Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
Deputy Centre Lead
Centre for Experimental Cancer Medicine
Barts Cancer Institute
Queen Mary University of London
Professor of Urology Cancer
Director of Barts Cancer Centre
Department of Cancer
St Bartholomew's Hospital (Barts Health NHS Trust)
London, United Kingdom
Professor of Medical Oncology
Head of Medical Oncology
Department of Medical Oncology
Bordeaux University Hospital,
Senior Clinical Editor
Associate Director, Scientific Services
Senior Director, Global Medical Education, Europe
Senior Director, Educational Strategy
This targeted program is designed to both inspire and instruct urologists, medical oncologists, and other healthcare providers caring for patients with urothelial cancer (UC) around the world and especially in Europe (Big 5 EU and Switzerland) and South America (Argentina). The identified target audience will benefit from this education by gaining the knowledge necessary to integrate the use of immune checkpoint inhibitors (ICI) into the treatment of advanced UC.
This program has been made available online.
From Clinical Care Options (CCO), watch video featuring expert perspectives on the use of immunotherapy for HCC
Commentary by Heather McArthur, MD: clinical implications of FDA approval for pembrolizumab plus chemotherapy in PD-L1–positive advanced TNBC from CCO
Matthew Galsky, MD, discusses the evolving use of immunotherapy in urothelial carcinoma, from Clinical Care Options (CCO)
In slides from Clinical Care Options (CCO), experts provide insights on the optimal treatment of advanced HCC